| Id: | acc0540 |
| Group: | 1sens |
| Protein: | Smad2 |
| Gene Symbol: | SMAD2 |
| Protein Id: | Q15796 |
| Protein Name: | SMAD2_HUMAN |
| PTM: | phosphorylation |
| Site: | Thr8 |
| Site Sequence: | --MSSILPFTPPVVKRLLGWK |
| Disease Category: | Cancer |
| Disease: | Pancreas Cancer |
| Disease Subtype: | |
| Disease Cellline: | PANC-1 |
| Disease Info: | |
| Drug: | metformin |
| Drug Info: | "Metformin is an oral antihyperglycemic agent used primarily in the treatment of type 2 diabetes, which works by reducing hepatic glucose production and enhancing peripheral insulin sensitivity." |
| Effect: | modulate |
| Effect Info: | "Metformin reduces the phosphorylation of Smad2/3 in pancreatic cancer cells, thereby inhibiting tumors." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 29956804 |
| Sentence Index: | 29956804_6 |
| Sentence: | "Furthermore, metformin reduced TGF-beta1 production and Smad2/3 phosphorylation in pancreatic cancer cells." |
Sequence & Structure:
MSSILPFTPPVVKRLLGWKKSAGGSGGAGGGEQNGQEEKWCEKAVKSLVKKLKKTGRLDELEKAITTQNCNTKCVTIPSTCSEIWGLSTPNTIDQWDTTGLYSFSEQTRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELKAIENCEYAFNLKKDEVCVNPYHYQRVETPVLPPVLVPRHTEILTELPPLDDYTHSIPENTNFPAGIEPQSNYIPETPPPGYISEDGETSDQQLNQSMDTGSPAELSPTTLSPVNHSLDLQPVTYSEPAFWCSIAYYELNQRVGETFHASQPSLTVDGFTDPSNSERFCLGLLSNVNRNATVEMTRRHIGRGVRLYYIGGEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGFEAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| SMAD2-Ser118 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -1.1 | ||||||||
| HGSC | |||||||||
| ccRCC | 0.246 | ||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | 0.854 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| SMAD2-Thr172 | |
|---|---|
| Cancer | Intensity |
| BRCA | 0.002 |
| COAD | -0.816 |
| HGSC | 1.954 |
| ccRCC | -0.467 |
| GBM | |
| HNSC | -0.115 |
| LUAD | -0.6 |
| LUSC | 0.334 |
| non_ccRCC | -1.011 |
| PDAC | -0.765 |
| UCEC | 1.485 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| - | - | A | Salivary adenoid cystic carcinoma | Phosphorylation | 21441221 |
| K | 451 | D | Renal fibrosis | Acetylation | 37777567 |
| T | 220 | D | Pancreatic ductal adenocarcinoma | Phosphorylation | 27014871 |
| S | 250 | D | Pancreatic ductal adenocarcinoma | Phosphorylation | 27014871 |
| - | - | D | Hepatocellular carcinoma | Ubiquitination | 35509688 |
| - | - | P | Pancreatic cancer/carcinoma/adenocarcinoma | Phosphorylation | 24334458 |
| - | - | P | Pre-eclampsia | Phosphorylation | 22832245 |
| - | - | P | Gastric cancer | Ubiquitination | 32226309 |
| S | 465 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 ; 35022323 |
| S | 465 | U | Marfan syndrome | Phosphorylation | 15731757 |
| S | 467 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 ; 35022323 |
| S | 467 | U | Marfan syndrome | Phosphorylation | 15731757 |
| T | 220 | U | Breast cancer | Phosphorylation | 33051597 |
| - | - | U | Ovarian cancer | Phosphorylation | 35293014 |
| S | 465 | U | Gastric cancer | Phosphorylation | 23934187 |
| - | - | U | Breast cancer | Ubiquitination | 33649832 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| Q15796 | SMAD2 | P | Thr8 | SSILPFT(ph)PPVVK | A431 | Afatinib | 7.9807 | - | |
| Q15796 | SMAD2 | P | Thr8 | SSILPFT(ph)PPVVK | A431 | Afatinib | 7.0973 | - | |
| Q15796 | SMAD2 | P | Thr8 | SSILPFT(ph)PPVVK | A431 | Afatinib | 8.768 | - | |
| Q15796 | SMAD2 | P | Thr8 | SSILPFT(ph)PPVVK | A431 | Afatinib | 7.7933 | - | |
| Q15796 | SMAD2 | P | Thr8 | SSILPFT(ph)PPVVK | A431 | Dasatinib | 6.9025 | - | |
| Q15796 | SMAD2 | P | Thr8 | SSILPFT(ph)PPVVK | A431 | Dasatinib | 6.5827 | - | |
| Q15796 | SMAD2 | P | Thr8 | SSILPFT(ph)PPVVK | A431 | Dasatinib | 6.287 | - | |
| Q15796 | SMAD2 | P | Thr8 | SSILPFT(ph)PPVVK | A431 | Gefitinib | 3.159 | - | |
| Q15796 | SMAD2 | P | Thr8 | SSILPFT(ph)PPVVK | A431 | Gefitinib | 2 | - | |
| Q15796 | SMAD2 | P | Thr8 | SSILPFT(ph)PPVVK | A431 | Gefitinib | 6.2915 | - | |
| Q15796 | SMAD2 | P | Thr8 | SSILPFT(ph)PPVVK | HeLa | SAHA | 9.42 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
